MARKETWIRE.NET

Decode Your Next Market Move

Ready Yourself for Challenges in the Time of COVID-19. Here’s What Stakeholders Need to Know About the Evolving Global CNS Therapeutics Market

The global market for CNS Therapeutics is projected to reach US$137.7 billion by 2025, driven by the urgent need to address the unmet medical needs of neurological disorders.

Global Industry Analysts, Inc. (GIA) launches comprehensive analysis of industry segments, market trends, growth drivers, market share, size and demand forecasts on the global CNS Therapeutics market. The segments covered in the study include Segment (Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer's, Anti-Parkinson's, and Other Segments).

24 June 3:18 A.M., California/Marketwire/ - According to the new market research report, the global market for CNS Therapeutics is projected to reach US$137.7 billion by 2025, driven by the urgent need to address the unmet medical needs of neurological disorders. Diseases of the brain and mind range from epilepsy, stroke, migraine, Alzheimer`s, Parkinson`s, dementia, multiple sclerosis, brain injuries, neuroinfections, schizophrenia, psychosis and other mental disorders. With unmet needs continuing to persist, societal and healthcare burden continues to increase. Stroke and infections such as meningitis and encephalitis continue to be the leading cause of disability worldwide, pushing up the cost of nursing care, hospice and bringing down quality of life. The unmet needs are evident in all phases of drug development i.e. identification of therapeutic targets; optimization of lead compounds; gaps in toxicity and pharmacokinetics studies; and slow resolution of ethical issues, among others.

The need of the hour is innovation in developing more potent drugs and therapies. One of the reasons for the slower development of safe and effective drugs for neurology is the fact that the human brain is one of the most complex and highly organized organs in the universe. The brain is a highly sophisticated piece of organic system perfected over millions of years of evolution. Scientists continue to struggle to fathom the complex interaction of chemicals and neurons in the brain. Investments in drug development in neurology is risky since certain diseases like neuropsychiatric diseases are difficult to target, are poorly defined, cannot be easily assayed, and pose challenges in efficiently validating clinical efficiency of drugs during clinical trials as most diseases progress slowly and develop over the years. Strong opportunities for CNS focussed drugs therefore exists and compounding this need is the rapidly aging population and a parallel rise in Parkinson`s, Alzheimer`s, pain manifestations, cerebrovascular disorders, stroke, seizures, cognitive and memory disorders.

The scenario has created a healthy global pipeline of late stage drugs and the market is expected to benefit from rising acceptance of new therapies and new classes of drugs; increased demand for combination therapies; growing use of generics; and launch of new Alzheimer`s drugs including anti-amyloid proteins, cholinergic and nicotine receptor agonists, neuro protective drugs, vaccines and GABA receptor modulators. Better understanding of the electrochemical processes of the brain and development of disease-modifying therapies is driving growth in the antiepileptic drugs market. Combination CNS Therapies are especially gaining prominence for their ability to target multiple pathologic processes simultaneously. Volume of CNS prescriptions for chronic pain and psychiatric disorders will grow in the coming years as the burden of mental illnesses intensifies as a result of lifestyle and societal changes and physiological stress. The growing focus on healthcare cost containment and rationalization and legislation of policies that encourage physician prescription of generic drugs will encourage sales of generic CNS medications.

A key trend in the market is pharma companies` efforts to restrategize CNS drug development, which still continues to cost significantly higher than development costs in other therapeutic areas. Increased use of contract research organization services; and predictive planning to prevent late stage drug failure are few of the strategies adopted to infuse vigor in the CNS drug development space. The United States and Europe represent large markets worldwide with a combined share of 70% of the market. China ranks as the fastest growing market with a CAGR of 7.3% over the analysis period supported by factors such as changing social structures and increased risk of developing psychiatric disorders such as schizophrenia, sleep disorders, depression and anxiety; growing literacy rates, improved awareness and gradual reduction in the stigma associated with neurological disorders; and government policy led development of healthcare delivery systems.

Key Competitors Covered in the Report
AbbVie Inc.
Alkermes Plc.
Allergan Plc.
AstraZeneca Plc.
Bristol-Myers Squibb
Eisai Co. Ltd.
Eli Lilly and Co.
Endo Pharmaceuticals Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
H. Lundbeck A/S
Janssen Pharmaceuticals Inc.
Merck & Co.Inc.
Neurocrine Biosciences Inc.
Novartis AG
Otsuka Pharmaceutical Co. Ltd.
Pfizer Inc.
Purdue Pharma L.P.
Sanofi
Shire Plc
Sumitomo Dainippon Pharma Co. Ltd.
Takeda Pharmaceutical Co. Ltd.
Teva Pharmaceutical Industries Ltd.
UCB Group

Geographies Analyzed in the Report
United States
Canada
Japan
China
Europe (France, Germany, Italy, United Kingdom, Spain, Russia, and Rest of Europe)
Asia-Pacific (Australia, India, South Korea, and Rest of Asia-Pacific)
Latin America (Argentina, Brazil, Mexico, and Rest of Latin America)
Middle East (Iran, Israel, Saudi Arabia, United Arab Emirates, and Rest of Middle East)
Africa

More details

Research Methodology
This latest edition of the research study is conducted and published by Global Industry Analysts, Inc., in close collaboration with senior executives in the industry driving strategy, business development, marketing, sales, product management, technology and operations. All analysis and findings published in the report are based on validated engagements from a total executive pool size of 10879. Among this pool, 1303 direct interactions with domain experts were carried out via our proprietary market research platform, MarketGlass. Among the 326 unique participations, a total of 147 validated responses were received as part of this report's primary research outreach program. We are unique in the industry to provide our clients with the validated list executive engagements and the complete project data stack.

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) (www.strategyr.com) is the world's only influencer driven AI powered market research company. Serving more than 41,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for 33 years, offering the widest coverage of topics, geographic markets, competitive brands, and companies profiled.

Contact Us:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
Email: sales@StrategyR.com